Skip to content
About

About

Lab image

about the company

Firebrick Pharma

Firebrick Pharma has developed a broad-spectrum anti-viral nasal spray that could be an effective treatment for preventative respiratory viral infections, such as the common cold.

Firebrick Pharma Pty Ltd is an Australian private company, founded in 2012 by two experienced pharmaceutical and biotech executives.

Drawing on their expertise in drug development and respiratory viral diseases, their vision was to create a treatment for the common cold using an entirely innovative approach.

THE FIREBRICK BREAKTHROUGH

In treating respiratory viral illnesses, such as the common cold, the challenge has always been that the infection of the nasal passages can be caused by any one of 200 or more viruses from at least six major groups.

The problem is that we rarely know the culprit and they can mutate, making a vaccine or targeted drug therapy impossible; that’s why no one has been able to develop a vaccine or anti-viral drug for colds.

At Firebrick, we took an innovative approach, using a unique chemical agent which has been shown to kill all the known viruses that can cause colds, and yet is safe for use in the nose. What’s more, because of the non-selective way it kills viruses, there has never been a report of viral resistance to the agent.

The Firebrick nasal spray is designed to rapidly degrade the virus population in the nasal passages and interrupt the infection cycle, potentially reducing the severity of cold symptoms.

Firebrick Viruses

History

  • 2012

    Firebrick Pharma Pty Ltd incorporated by Peter Molloy and Stephen Goodall with the mission to create a microbicidal nasal spray to treat the common cold.

  • 2013

    Product development commences.

  • 2014

    Australian patent filed.

  • 2015

    Australian patent granted and international patent filings commence. Formulation development commences in Melbourne laboratories.

  • 2016

    Series A funding closes; product development accelerates.

  • 2017

    Product formulation, packaging and manufacturing development completed; viral inactivation studies confirm activity.

  • 2018

    Safety testing models indicate product is safe for nasal use; new patents filed; Series B funding closes. Phase 1 and Phase 2 trials completed.

  • 2019

    Series C funding, Phase 3 trial completed, new patent filed.

Firebrick Pharma Team

Peter M

Peter L Molloy

Chairman & Founder, BSc, MBA, FAICD, PhD

Peter Molloy trained as a microbiologist and biochemist and subsequently built a successful career in the international pharmaceutical industry. At Pharmacia (Pfizer) he was Managing Director of Australia/NZ operations and later Vice President for Strategic Marketing, responsible for the marketing of hundreds of pharmaceuticals across 22 countries. During his pharmaceutical career, he has directly launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals. Subsequently, as CEO of four biotech companies, he has led numerous R&D programs, moved several drugs from research into human clinical trials, and executed valuable international pharmaceutical partnerships including two $100m+ licensing deals. In 2002-2005, he was CEO of one of the world's leading antiviral research companies, Biota Holdings Limited, where during his term the company’s market value increased from $30m to around $300m. He has extensive knowledge and expertise in the development and marketing of oral and topical antimicrobial agents, and at Biota managed R&D programs focused on new drug treatments for respiratory viral diseases.

Stephen G

Stephen Goodall

COO & Co-founder, BAppSc, MAppSc, MBA, PhD

Stephen Goodall has a successful track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was Chief Operating Officer of Viralytics, which was successfully acquired in 2018 for $500 million by the US big pharma company, Merck. Previously, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical for 11 years. He has extensive experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has an impressive background in process development, production scale-up and GMP manufacturing for pharmaceuticals.

Linda F

Linda Friedland

Head of Business Development, MD, GAICD

Dr Linda Friedland is the head of Business Development at Firebrick Pharma. She is a physician with more than 20 years’ experience in clinical medicine which she has combined with strategy and governance expertise. She consults internationally to healthcare, biotech, corporate and financial institutions. Among her other roles, Dr Friedland is, senior consultant to TargImmune Therapeutics (Basel, Switzerland), clinical and scientific advisor to Shanghai-based Joint US China Clean Energy Commission (JUCCE), and a director on the board of the Neurology Council of Western Australia. She has developed public health and disease management programs in Asia, US, Australia, Africa and the UK. Dr Friedland is an author and an a international speaker.

Peter K

Peter Kash

Business Advisor, BS, MBA, EdD

Dr. Peter Kash is a Board Member and the Company’s global Business Advisor based in Florida. Peter Kash worked on Wall Street for 30 years and is a renowned biotech entrepreneur, who has raised at least US$1 billion for private biotech companies and co-founded more than a dozen companies, which collectively have six FDA-approved drugs. He is currently a co-founder and Vice-Chairman of TargImmune Therapeutics, an oncology platform company in Switzerland. Dr Kash holds a BSc in Management Science, an MBA in Banking and International Finance and a Doctorate in Education. He has held Adjunct, Associate and Visiting Professorships at the Wharton School of Business, Hebrew University in Jerusalem and Nihon University in Tokyo, as well as lectured worldwide and authored and co-authored several books.

Peter-Friedland-Firebrick

Professor Peter Friedland

Chief Medical Officer, MBBCh MMed FRACS FCS (SA)

Professor Peter Friedland is the Company’s Chief Medical Officer. Prof Friedland is an ENT (ear, nose and throat) specialist, associate professor at the University of Western Australia and professor at the University of Notre Dame, Fremantle. He holds several national appointments including memberships of the board of the Australian Society of Otorhinolaryngology Head & Neck Surgery at Royal Australian College of Surgeons (RACS), the Panel of Clinical Experts for the Australian Government Department of Health and the MBS (Medical Benefit Schemes) National ENT Taskforce. Prof Friedland, a surgeon scientist at Sir Charles Gairdner hospital and Joondalup Health Campus. He is currently engaged in multidisciplinary clinical research in head and neck cancer, hearing loss rehabilitation and nasal disease. In the last decade, he has published more than 50 peer reviewed scientific articles and delivered more than 150 conference presentations and invited lectures. Prior to immigrating to Australia in 2009, he was clinical head of the ENT department at the University of Witwatersrand, Donald Gordon Medical Centre, Johannesburg, South Africa. Prof Friedland was appointed Mr. Nelson Mandela’s ENT specialist from 2000 to 2009.

Simon-Tucker-pp

Simon Tucker

Chief Scientific Officer, BSc (Hons), PhD

Dr Simon Tucker is a virologist with decades of pharmaceutical R&D management experience.  He previously led teams at GD Searle (US) focused on new antivirals including influenza and HIV, where he was a member of the team responsible for the discovery of the HIV protease inhibitor, amprenavir.  He subsequently led the Gene Therapy Group at the University of Glasgow (UK), before joining Biota Pharmaceuticals, the world-leading antiviral drug developer at the time.  As Vice President of Research at Biota he oversaw the research and IP portfolios, managed the R&D strategy and execution, and was directly involved in multiple licensing deals, collaborative projects with major pharmaceutical companies and the discovery and progression of clinical candidates.  He led the teams that discovered zanamivir (Relenza), the world’s first neuraminidase inhibitor for treatment of influenza, as well as the world’s first point of care diagnostic test for influenza A and B. He also presided over the discovery and development of candidate drugs for the common cold (vapendavir), RSV and hepatitis C .  He is a founder & former CEO at 360biolabs and is currently Chairman of Jumpstart-Fertility, an international biotech focused on drugs to address female infertility.